JNJ vs GILD Comparison: AI Score, Valuation, Performance and Upside
Compare Johnson & Johnson's diversified drug and medtech portfolio against Gilead's concentrated HIV treatment dominance and growing oncology business.
Use this Johnson & Johnson vs Gilead Sciences comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
GILD holds the edge across 3 of 5 key metrics in this comparison. JNJ has delivered stronger 1-year price return (+50.62% vs +30.00%), though GILD has the better forward P/E setup (14.73x vs 21.78x for JNJ). GILD leads on both revenue growth (10.20%) and operating margin (33.68%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for GILD (+8.05%) than for JNJ (+1.66%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | JNJ | GILD |
|---|---|---|
| AI scorei | 49.9 | 42.9 |
| AI ranki | #553 | #899 |
| Latest closei | $267.20 | $146.30 |
| 1M returni | +2.63% | +5.74% |
| 6M returni | +12.22% | +1.32% |
| 1Y returni | +50.62% | +30.00% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | JNJ | GILD |
|---|---|---|
| 1Y ago | $15.14K (+51.4%) started 2025-09-16 | $13.2K (+32.0%) started 2025-09-16 |
| 5Y ago | $19.96K (+99.6%) started 2021-09-17 | $27.25K (+172.5%) started 2021-09-17 |
| 10Y ago | $37.29K (+272.9%) started 2016-09-19 | $36.72K (+267.2%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | JNJ | GILD |
|---|---|---|
| Market capi | $645.95B | $180.64B |
| Trailing P/Ei | 31.06 | 17.74 |
| Forward P/Ei | 21.78 | 14.73 |
| Price/Salesi | 4.18 | 4.87 |
| EV/Revenuei | 6.88 | 6.63 |
| Analyst targeti | $272.50 | $157.41 |
| Target upsidei | +1.66% | +8.05% |
| Metric | JNJ | GILD |
|---|---|---|
| Revenue growthi | 6.60% | 10.20% |
| Earnings growthi | -0.90% | 54.80% |
| EPS growthi | -0.90% | +54.80% |
| FCF margini | +17.24% | +32.07% |
| Operating margini | 29.19% | 33.68% |
| Profit margini | 21.48% | -10.64% |
| ROIC proxyi | 25.74% | -20.68% |
| Return on equityi | 25.74% | -20.68% |
| Dividend yieldi | 2.00% | 2.20% |
| Payout ratioi | 60.79% | 43.40% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.23 | 0.34 |
| Debt/equityi | 57.71 | 223.47 |
| Current ratioi | 1.09 | 1.26 |
| Quick ratioi | 0.72 | 0.90 |
Over the past year, JNJ and GILD have moved weakly in the same direction (correlation of 0.38), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | JNJ | GILD |
|---|---|---|---|
| 1Y | Growthi | +51.42% | +31.97% |
| CAGRi | +51.55% | +32.04% | |
| Volatilityi | 19.11% | 26.49% | |
| Sharpe ratioi | 2.04 | 1.01 | |
| Sortino ratioi | 3.24 | 1.60 | |
| Max drawdowni | 10.96% | 22.03% | |
| Current drawdowni | 4.03% | 6.10% | |
| Avg drawdowni | 2.94% | 8.00% | |
| Ulcer Indexi | 4.12% | 10.23% | |
| Max daily dropi | 3.66% | 3.72% | |
| Max wkly dropi | 6.22% | 5.98% | |
| 5Y | Growthi | +79.51% | +134.93% |
| CAGRi | +12.42% | +18.64% | |
| Volatilityi | 17.61% | 24.78% | |
| Sharpe ratioi | 0.50 | 0.63 | |
| Sortino ratioi | 0.74 | 0.98 | |
| Max drawdowni | 18.41% | 26.59% | |
| Current drawdowni | 4.03% | 6.10% | |
| Avg drawdowni | 7.01% | 9.00% | |
| Ulcer Indexi | 8.57% | 10.96% | |
| Max daily dropi | 7.59% | 10.15% | |
| Max wkly dropi | 9.18% | 9.78% | |
| 10Y | Growthi | +186.90% | +153.87% |
| CAGRi | +11.13% | +9.77% | |
| Volatilityi | 18.84% | 25.59% | |
| Sharpe ratioi | 0.42 | 0.32 | |
| Sortino ratioi | 0.59 | 0.47 | |
| Max drawdowni | 27.37% | 30.47% | |
| Current drawdowni | 4.03% | 6.10% | |
| Avg drawdowni | 6.41% | 13.27% | |
| Ulcer Indexi | 7.97% | 15.17% | |
| Max daily dropi | 10.04% | 10.15% | |
| Max wkly dropi | 13.25% | 12.29% |
| Category | JNJ | GILD |
|---|---|---|
| Company | JNJ | GILD |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. | Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.